Drug – bio-affecting and body treating compositions – Enzyme or coenzyme containing – Multienzyme complexes or mixtures of enzymes
Reexamination Certificate
2004-03-01
2010-11-23
Long, Scott (Department: 1633)
Drug, bio-affecting and body treating compositions
Enzyme or coenzyme containing
Multienzyme complexes or mixtures of enzymes
C435S007230
Reexamination Certificate
active
07837991
ABSTRACT:
Method of cancer treatment by controlling cellular p53 protein levels. The invention concerns, in particular, the use of a compound capable of modulating calpaine activity.
REFERENCES:
patent: 4788219 (1988-11-01), Sakurai et al.
patent: 5496731 (1996-03-01), Xu et al.
patent: 5607831 (1997-03-01), Henkart et al.
patent: 5629165 (1997-05-01), Nixon et al.
patent: 159 678 (1985-10-01), None
patent: 395 309 (1990-10-01), None
patent: 569 122 (1993-11-01), None
patent: 569122 (1993-11-01), None
patent: 580 161 (1994-01-01), None
patent: 92/21373 (1992-12-01), None
patent: WO 92/21373 (1992-12-01), None
patent: WO/92/21373 (1992-12-01), None
patent: WO93/02106 (1993-02-01), None
patent: WO 93/02106 (1993-02-01), None
patent: WO 94/21817 (1994-09-01), None
patent: WO 00/21575 (2000-04-01), None
Asada et al. J. Enzym. Inhib. 3 (1), 49-56 (1989).
Rambsy et al. Electrophoresis. Feb. 1994;15(2):265-77.
Carafoli et al. (Biochemical and Biophysical Research Communications, 1998; 247: 193-203).
Squier et al. (Journal of Cellular Physiology, May 1994; 159(2): 229-237).
Maki et al. (The Journal of Biological Chemistry, Nov.15, 1989; 264(32): 18866-18869).
Haake et al. (J Invest Dermatol, 1993; 101: 107-112).
Lowe et al. (Nature. Apr. 29, 1993; 362: 847-849).
Robaye et al. (Electrophoresis. 1994; 15: 503-510).
Lane et al (British Medical Bulletin. 1994; 50(3):582-599).
Huibregtse et al. (Molecular and Cellular Biology. Aug. 1993; 13(8): 4918-4927).
Huibregtse et al. (EMBO Journal. 1991; 10(13): 4129-4135).
Marshall; Gene Therapy 's Growing Pains, 1995, Science, vol. 269: 1050-1055.
Asada et al., “cDNA cloning of human calpastatin: sequence homology among human, pig, and rabbit calpastatins.” J. Enzym. Inhib., vol. 3 (1): 49-56, 1989.
Bischoff et al., “An adenovirus mutant that replicates selectively in p53-deficient human tumor cells.” Science, vol. 274 : 373-376, Oct. 1996.
Miller et al., “Targeted vectors for gene therapy.” FASEB, vol. 9: 190-199, Feb. 1995.
Crystal, RG., “Transfer of Genes to Humans: Early lessons and obstacles to success.” Science, vol. 270: 404-410, 1995.
Dach et al., “Targeting gene therapy to cancer: a review.” Oncology Res., vol. 9: 313-325, 1997.
Verma et al., “Gene therapy—promises, problems and prospects.” Nature, vol. 389: 239-242, Sep. 1997.
Deonarain, MP., “Ligand-targeted receptor-mediated vectors for gene delivery.” Exp. Opin. Ther. Patents, vol. 8 (1): 53-69, 1998.
Eck et al., “Gene-based therapy.” Goodman & Gilman's The Pharmacological Basis of Therapeutics, McGraw-Hill-Nith Edition: 77-101, 1996.
Orkin et al., “Report and recommendations of the panel to assess the NIH investment in research on gene therapy.” pp. 1-20, Dec. 1995.
Orkin et al (1995) Report and Recommendation of the Panel to Access the NIH Investment in Research on Gene Therapy.
Y Emori et al (1988) J Biol Chem 263: 2364-2370.
H Witschi et al (1989) Carcinogenesis 10: 2275-2277.
W Troll et al (1984) JNCI.73: 1245-1250.
M Ohkoshi (1980) Gann 71: 246-250.
Levrero etal (1991) Gene 101: 195-202.
Maki etal (1989) J. Biol. Chem 264: 18866-18869.
Anderson, W. French, Nature Medicine, vol. 6, No. 8, p. 862 (Aug. 2000).
Wagenknecht et al., “Proteasome Inhibitors Induce p53/p21-Independent Apoptosis in Human Glioma Cells”, Cell Physiol Biochem 1999; 9:117-125.
An et al., “Protease inhibitor-induced apoptosis: accumulation of wt p53, p51 WAF1/CIP1,and induction of apoptosis are independent markers of proteasome inhibition”, Leukemia (2000) 14; 1276-1283.
Kubbutat et al., “Proteolytic Cleavage of Human p53 by Calpain: a Potential Regulator of Protein Stability”, Molecular and Cellular Biology, Jan. 1997; pp. 460-468.
Kubbutat and Vousden, “Keeping an old friend under control: regulation of p53 stability”, Molecular Medicine Today, Jun. 1998; pp. 250-256.
Atencio et al., “Celpain Inhibitor 1 Activates p53-dependent Apoptosis in Tumor Cell Lines”, Cell Growth & Differentiation, May 2000; vol. 11, 247-253.
Pariat, et al., “Proteolysis by Calpains: a Possible Contribution to Degradation of p53”, Milecular and Cellular Biology, May 1997; vol. 17 No. 5, pp. 2806-2815.
Carafoli, et al., “Breakthrough and Views Calpain: A Protease in Search of a Function?”, Biochemical and Biophysical Research Communications 247, 193-203 (1998).
Levrero et al., Defective and Nondefective Adenovirus Vectors for Expressing Foreign Genes In Vitro and In Vivo, Gene, 101, 195-202, (1991).
Maki et al., Inhibition of Calpain by a Synthestic Oligopeptide Corresponding to an Exon of the Human Calpastatin Gene, Journal of Biol. Chemistry, 264, (32), 18866-18869, (1989).
Ohkoshi, Effect of Aprotinin on Growth of 3-Methylcholanthrene-Induced Squamous Cell Carcinoma In Mice, Gann 71: 246-250 (1980).
Troll et al., Protease Inhibitors as Anticarcinogens, JNCL 73(6): 1245-1250 (1984).
Emori et al., All Four Repeating Domains of the Endogenous Inhibitor for Calcium-dependent Protease Independently Retain Inhibitory Activity, Journal of Biological Chemistry 263(5): 2364-2370 (1988).
Witschi et al., Modulation of lung tumor development in mice with the soybean-derived Bowman-Birk protease inhibitor, Carcinogenesis 10:2275-2277 (1989).
Orkin et al., Report & Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy, NIH (1995).
Carillo et al., Differential sensitivity of FOS and JUN family members to calpains, Oncogene 9, 1679-1689 (1994).
Y. Emori et al. All Four Repeating Domains of the Endogenous Inhibitor for Calcium-dependent Protease Independently Retain Inhibitory Activity, J. Biol Chem 263:2364-2370;1988.
H. Witschi et al. Modulation of lung tumor development in mice with the soybean-derived Bowman-Birk protease inhibitor, Carcinogenesis 10:2275-2277 (1989).
W. Trolli et al. Protease Inhibitors as Anticarcinogens, JNCI 73 (6):1245-1250, date=1984 ; author=Troll.
M. Ohkoshi (1980) Gann 71: 246-250.
Carillo et al., “Differential sensitivity of FOS and JUN family members to calpains”, Oncogene 9, 1679-1689 (1994).
Levrero et al., “Defective and Nondefective Adenovirus Vectors for Expression Foreign Genes in Vitro and In Vivo”, Gene, 101, 195-202, (1991).
Maki et al., “Inhibition of Calpain by a Synthestic Oligopeptide Corresponding to an Exon of the Human Calpastain Gene” Journal of Biol. Chemistry, 254, (32), 18866-18869 1989.
Ohkoshi, “Effect of Aprotinin on Growth of 3-Methylcholanthrene-Induced Squamous Cell Carcinoma in Mice”, Gann 71: 246-250 (1980).
Orkin, et al., “Report & Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy”, NIH, 1-20 (Dec. 1995).
Dach, et al. “Targeting gene therapy to cancer: A Review”, Oncology rES., vol. 9: 313-325, 1997.
Verma et al., “Gene therapy—promises, problems and prospects”, Nature, vol. 389: 239-242 (Sep. 1997).
Eck et al., “Gene-based therapy”, Goodman & Gilman's The Pharmacological Basis of Therapeutics, McGraw-Hill Nith Edition: 77-101. (1996).
Asada et al., “cDNA cloning of human calpastain; sequence homology among human, pig, and rabbit calpastatins” J. Enzym. Inhib., vol. 3(1): 49-56 (1989).
Bischoff et al., “An adenovirus mutant that replicates selectively in p53-deficient human tumor cells.” Science, vol. 274:373-376. (Oct. 1996.
Miller et al., “Target vectors for gene therapy”, FASEB, vol. 9: 190-199 (Feb. 1995).
Crystal, RG., “Transfer of Genes to Humans: Early lessons and obstacles to success”, Science, vol. 270: 404-410. (1995).
Marshall, “Gene Therapy's Growing Pains”, Science, vol. 269:1050-1055 (1995).
Anderson, W. French, Nature Medicine, vol. 6 No. 8, p. 862 (Aug. 2000).
Wagenknecht, et al., “Proteasome Inhibitors Induces p53/p21-Independent Apoptosis in Human Giloma Cells”,
Blanchard Jean-Marie
Carillo Serge
Piechaczyk Marc
Aventis Pharma S.A.
Long Scott
Wiley & Rein LLP
LandOfFree
Method of cancer treatment by p53 protein control does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of cancer treatment by p53 protein control, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of cancer treatment by p53 protein control will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4169044